On September 1, 2022 Medigene AG ( View Source) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, reported that it will participate at the following upcoming scientific conferences (Press release, MediGene, SEP 1, 2022, View Source [SID1234618900]). Medigene’s management and/or scientists will be available for one-on-one meetings at these events.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

7th CAR-TCR Summit
19-22 September 2022
Boston, MA, USA
https://car-tcr-summit.com/

Immuno UK
29-30 September 2022
London, United Kingdom
View Source

10th Annual Immuno-Oncology Summit
12-14 October 2022
Boston, MA, USA
https://www.immuno-oncologysummit.com/

Cell UK
7-8 November 2022
London, United Kingdom
View Source